1 Meyer-Rosberg, K et al. Peripheral neuropathic pain-a multidimensional burden for patients. Eur J Pain 2001;5:379 – 89.
2 Colloca, L et al. Neuropathic pain. Nat Rev Dis Primers 2017;3:17002.
3 Anand, P & Bley, K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high concentration capsaicin 8 % patch. Br J Aneasth 2011;107:490 – 502.
4 Gibbons, CH et al. Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann Neurol 2010;68:888 – 98.
5 Chiang, H et al. Physiological and pathological characterization of capsaicin-induced reversible nerve degeneration and hyperalgesia. Eur J Pain 2018;22:1043 – 56.
6 Mou, J et al. Efficacy of Qutenza^® (capsaicin) 8 % patch for neuropathic pain: a meta-analysis of the Qutenza^® clinical trials database pain 2013;154:1632 – 9.
7 van Nooten, F et al. Capsaicin 8 % patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther 2017;39:787 – 803.
8 Vinik, AI et al. Repeat treatment with capsaicin 8 % patch (179 mg capsaicin cutaneous patch): effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial. J Curr Med Res Opin 2019;2:388 – 401.
9 Vinik, AI et al. Capsaicin 8 % patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol 2016;16:251.
10 Gálvez, R et al. Capsaicin 8 % patch repeat treatment in nondiabetic peripheral neuropathic pain: a 52-Week, open-label, single-arm, safety study. Clin J Pain 2017;33:921 – 31.
11 Fachinformation Qutenza, Stand 10/2023

Progressives Ansprechen bei Mehrfachapplikation des Capsaicin-Pflasters (179mg / 8%)